NMPA approved Siponimod for RMS in China

2020.5.11 NMPA published the new drug approval news. Siponimod from Novartis was approved under priority review for relapsing multiple sclerosis.

The following comes from Wikipedia:
Siponimod, sold under the brand name Mayzent, is a selective sphingosine-1-phosphate receptor modulator for oral use that is used for multiple sclerosis (MS). It is intended for once-daily oral administration.
In March 2019, it was approved in the United States to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

Popular posts from this blog

Shanghai Xunhe Pharma’s CDK4/6 Inhibitor XH-30002 IND Accepted by Chinese NMPA

Guideline on the Submission of Clinical Trial Data in China (2020.5 Draft for Public Review)

Drug Review Package of Chinese New Chemical or Biologic Drug